FREEZE-DRIED LECITHIN NANOMETER POWDER INJECTION OF URSOLIC ACID AND IT'S PREPARATION METHOD

/Home/Lyophilization and Protein Formulation Patents/Patent Articles - Lyophilization/European Patents - Lyophilization

Patent Number: WO2004045619
Publication date: 2004-06-03
Inventor(s): XIE JUNMING [CN]; BAI YAN [CN]; YI YIMU [CN]; YANG GUANG [CN]; ZHANG CHANGGONG [CN]
Applicant(s): WUHAN LIYUANHENG PHARMACEUTICA [CN];; XIE JUNMING [CN];; BAI YAN [CN];; YI YIMU [CN];; YANG GUANG [CN];; ZHANG CHANGGONG [CN]
Requested Patent: WO2004045619
Application Number: WO2003CN00969 20031117
Priority Number(s): CN20020147711 20021121
IPC Classification: A61K31/56; A61K9/19; A61P35/00; A61P29/00
EC Classification: A61K9/19, A61K31/19
Equivalents: CN1410064
Cited Documents: CN1157716; CN1333679; CN1266680
Abstract
The invention disclosed a freeze-dried nanometer powder injection of ursolic acid. It major compose of active material of ursolic acid, complex vehicle of nanometer powder, excipient of freeze-drying. Compare to other popular preparations, its advantages are high target application of liver, concentrate on the affects, increase curative effect, decrease side effect, high dispersity and stability. It is prepared through dissolving ursolic acid as active raw material in medical organic solvent, adding complex vehicle of bean lecithin and stearic acid, stirring while heating until reaction completed, adding distilled water, adding excipient, stirring while heating until reaction completed, filtering with microporous membrane and freeze-drying the filtrate. Its average particle size is 209.5 nm, comprise of 25.2% drug. It is for inhibiting and treating liver cancer, decreasing expression of p53, bcl-2 and topo-II.

Data supplied from the esp@cenet database - l2